Amgen Inc. (LON:0R0T)

Market Cap	127.38B
Revenue (ttm)	26.70B
Net Income (ttm)	3.27B
Shares Out	n/a
EPS (ttm)	6.04
PE Ratio	38.99
Forward PE	n/a
Dividend	7.19 (2.34%)
Ex-Dividend Date	May 16, 2025

Volume	7,073
Average Volume	2,232
Open	306.44
Previous Close	308.50
Day's Range	305.00 - 308.67
52-Week Range	253.20 - 330.26
Beta	n/a
RSI	47.17
Earnings Date	Apr 25, 2025

About Amgen

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1980
• Employees: 28,000
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0R0T

Financial Performance

In 2024, Amgen's revenue was $33.42 billion, an increase of 18.57% compared to the previous year's $28.19 billion. Earnings were $4.09 billion, a decrease of -39.11%.

Financial numbers in USD